Helicos BioSciences Corporation
One Kendall Square
Building 700
Cambridge,
MA 02139
United States - Map
Phone: 617-264-1800
Fax: 617-264-1700
Web Site: http://www.helicosbio.com
| Helicos BioSciences Corporation, a life sciences company, focuses on genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets. The companys products are based on its proprietary True Single Molecule Sequencing technology, which enables the analysis of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. Its Helicos genetic analysis platform consists of HeliScope single molecule sequencer; HeliScope analysis engine, an image analysis computer tower; associated reagents, which are chemicals used in the sequencing process; and disposable supplies. The companys Helicos genetic analysis system is used for various applications in the areas of studying the human genome, disease association studies, cancer research, pharmaceutical research and development, infectious diseases, autoimmune conditions, clinical diagnostics, and agricultural research. Its customers include genome sequencing centers, biotechnology and pharmaceutical companies, and academic medical centers and research institutions in the United States and Canada. The company was formerly known as Newco LS6, Inc. and changed its name to Helicos BioSciences Corporation in November 2003. Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Ronald A. Lowy , 50
Chief Exec. Officer |
$
62.00K | N/A | Mr. Stephen J. Lombardi , 54
Pres, Chief Operating Officer |
N/A
| N/A | Dr. Noubar B. Afeyan Ph.D., 46
Co-Founder, Lead Independent Director and Chairman of Nominating & Corp. Governance Committee |
$
55.00K | N/A | Dr. J. William Efcavitch Ph.D., 57
Chief Technology Officer and Sr. VP |
$
289.00K |
$
411.00K | Dr. Stephen Quake D.phil.,
Co-Founder and Chairman of Scientific Advisory Board |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.14% Nasdaq 
Profile
